Disulfiram reduces metastatic osteosarcoma tumor burden in an immunocompetent Balb/c or-thotopic mouse model

INTRODUCTION: The overall survival rate of patients with osteosarcoma (OS) and pulmonary metastases has remained stagnant at 15–30% for several decades. Disulfiram (DSF) is an FDA-approved aldehyde dehydrogenase inhibitor that reduces the metastatic phenotype of OS cells in vitro. Here we evaluate i...

Descripción completa

Detalles Bibliográficos
Autores principales: Crasto, Jared Anthony, Fourman, Mitchell Stephen, Morales-Restrepo, Alejandro, Mahjoub, Adel, Mandell, Jonathan Brendan, Ramnath, Kavita, Tebbets, Jessica C., Watters, Rebecca J., Weiss, Kurt Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059028/
https://www.ncbi.nlm.nih.gov/pubmed/30046395
http://dx.doi.org/10.18632/oncotarget.25733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059028/
https://www.ncbi.nlm.nih.gov/pubmed/30046395
http://dx.doi.org/10.18632/oncotarget.25733

Ejemplares similares